DWRX 2008
Alternative Names: DWRX-2008Latest Information Update: 03 Oct 2023
At a glance
- Originator Daewoong Pharmaceutical
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 25 Sep 2023 Daewoong Pharmaceutical plans a phase I trial for diabetic retinopathy and diabetic macular oedema (In volunteers) in Q4 2023
- 14 Sep 2023 Ministry of Food and Drug Safety approves IND application for DWRX 2008 in Diabetic Retinopathy (Diabetic macular oedema)
- 30 Apr 2023 DWRX 2008 receives Korea Drug Development Fund (KDDF) designation for Diabetic Retinopathy